New combo therapy for brain cancer shows promise in early trial

This early-phase study tests whether adding a personalized vaccine (made from each patient's tumor mutations) to standard care plus Tumor Treating Fields is safe for people with newly diagnosed glioblastoma, an aggressive brain cancer. Thirteen adults with stable disease after initial treatment will receive the vaccine and continue standard therapy. The main goal is to check for side effects and see if the vaccine can be made and given successfully.